Cell death from STZ is thought to first require cellular uptake by GLUT-2, which is the mechanism by which peripherally administered STZ selectively kills cells of the pancreas, causing a type 1 diabetes phenotype [1,2,3]. The gene discussed is SLC2A2; the disease is type 1 diabetes mellitus.